NCT05547503 - Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

December 4, 2024

Study Completion Date

May 14, 2025

Conditions

Pain, NeuropathicPain, Inflammatory

Interventions

DRUG

AFA-281

Part 1: AFA-281 will be administered as a single dose at 4 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 - 21 days at 3 dose levels (TBD)

Trial Locations (1)

90720

CenExcel CNS, Los Alamitos